Join us at CVCF 2026 to explore how startups can scale and win in the age of AI.
Updated
October 29, 2026 11:39 PM
CVCF 2026 takes place on 4–5 November at Cyberport, Hong Kong. IMAGE: CYBERPORT
AI can help you build a startup, but it won’t automatically make you stand out. When everyone has access to similar tools, you need to give customers a reason to choose you and investors a reason to back you. So, how do you turn innovation into a competitive edge?
That question sits at the heart of Cyberport Venture & Capital Forum (CVCF) 2026, taking place on 4–5 November under the theme “Scaling in a Changing World: Winning the Next Competitive Cycle” and the message “Scale Up & Win.”
The two-day forum will feature more than 80 speakers discussing venture investment, AI-driven growth, emerging technologies and expansion into new markets. Day 1 will explore global investment trends and the next wave of innovation. Day 2 will feature CVCF 2026’s spotlight event, the Agentic Economy Summit, examining how agentic AI and digital assets could reshape business and finance. The wider programme will also include investor matching, founder pitches, 100+ Innovator Showcase, startup workshops and clinics.
With founders and investors navigating a fast-changing technology landscape, CVCF 2026 will explore what it takes to stay competitive, scale into new markets and turn emerging opportunities into business growth. Here’s a look at the key programmes lined up for this year’s forum.
Keynotes and Panels: Finding the Next Big Opportunity
Taara founder and CEO Mahesh Krishnaswamy will deliver the keynote The Innovation Playbook: Capitalizing on Moonshots and Faster Cycles in the Age of AI. The wider Day 1 programme will cover global investment trends, expansion into new markets, agentic AI and one-person companies.
For startups navigating the AI market, the panel Mastering the AI Bubble: Capital Rerouting and How Global Champions Stand Out will bring together panellists from Quona Capital, Alumni Ventures, FOV Ventures and Capital6 to discuss how investors assess startups and distinguish commercial potential from market hype. Other sessions will explore emerging technologies beyond AI software, including embodied AI, advanced computing and commercial aerospace.
Investor Matching and Networking: Connecting with Capital
Away from the conference sessions, MatchEasy will help founders and investors arrange one-to-one meetings, either onsite or online. Confirmed participants will receive access to the platform to explore potential matches and schedule meetings.
Investors can also discover local and international startups through the Founder Pitch programme, where entrepreneurs present their projects and ventures. Meanwhile, the Innovator Showcase offers a separate opportunity to explore emerging technology solutions through a virtual platform and selected on-site exhibits.
For founders seeking more tailored guidance, the Startup Clinics will offer one-to-one discussions with industry experts and experienced entrepreneurs on business challenges, fundraising and growth. Advance registration is required.
Hands-On Workshops: Strengthening Your Investment Pitch
Turning an innovative idea into a business that investors can back takes more than a strong pitch. CVCF 2026 will host practical workshops to help founders strengthen their fundraising strategies and make a stronger case to investors.
Led by Capital6 advisor Christine Keung, one workshop will explore how founders can align technical innovation with business goals, communicate their product’s value and prepare for fundraising. Another, led by Jeremy Dalton, advisor at FOV Ventures and SXSW Pitch, will help founders understand how investors assess startups, with opportunities to pitch live and receive direct feedback.
CVCF 2026’s spotlight event, the Agentic Economy Summit, will take place on 5 November under the theme “Intelligent Frontiers, Tokenised Horizons: Where Agentic AI Reshapes Business and Digital Assets Redefine How Value Moves.”
The summit will bring together technology and finance leaders to explore how agentic AI and digital assets could change the way businesses operate. Wolf Ruzicka, chief commercial officer at Unlimit, a global payments company, will discuss building and scaling agentic AI applications. Dr Feng Xiao, chairman and CEO of HashKey Group, will examine how digital identity, tokenised assets and money connect on-chain.
The discussions will also look at agent-led commerce, including how AI agents could help customers choose products and make purchases, and the payment systems needed to support these transactions. Other topics include Hong Kong dollar stablecoins and their potential role in payments and settlement, as well as the rise of one-person companies. The summit will also explore how founders can use AI agents to run their businesses with smaller teams, find customers and generate recurring revenue.
From AI-driven growth and cross-border investment to agentic AI and digital assets, CVCF 2026 brings together the people and ideas shaping the next phase of business. Whether you're preparing to raise capital, exploring new markets or assessing emerging technologies, the forum offers an opportunity to gain fresh perspectives and connect with investors, founders and industry leaders.
Exclusive for Ventureport readers: Use the promotional code cvcf26vp to access a Full Access Pass for HK$300, subject to confirmation of the offer by the organiser.
Date: 4–5 November 2026
Function Rooms, Level 3, Core E, Cyberport 3, Hong Kong
Keep Reading
A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.